Shared on 06 Aug 25

Fair value Decreased 41%

Despite improved profitability—with net profit margin rising to 12.26% and a lower future P/E of 47.56x—analysts have cut Y-mAbs Therapeutics’ consensus price target from $14.70 to $11.68, suggesting tempered growth expectations. What's in the News SERB S.A.S. agreed to acquire Y-mAbs Therapeutics for approximately $398.67 million ($8.6 per share); deal approved by Y-mAbs board and expected to close by December 31, 2025, subject to antitrust approval.

Read more

0 votesShare

Shared on 01 May 25

Fair value Decreased 14%

Read more

0 votesShare

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 17 Apr 25

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 46.4x to 51.8x.

Read more

0 votesShare

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 02 Apr 25

Fair value Increased 0.95%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare